Product profile · United States
JAKAFI
· Patent Litigation & Settlement History ↓
Current GenericRadar decision
GNR judgment: DEEP_REVIEW. Reference year: 2028. Anchor type: DS_EQUIVALENT_PATENT. Patent anchor: 2028-12-12. Exclusivity anchor: not recorded. Anchor date: 2028-12-12. Patent tail: no. Exclusivity tail: yes. Review status: FINAL. Historical detailed rationale is retained in the evidence snapshot; this is a structured English summary, not a literal translation.
Patent estate
| Patent | Effective date | Official listing | TRUE_DS | DS grade | Claim classification / basis | PTE | PED | Family |
|---|---|---|---|---|---|---|---|---|
| 9079912 | 2026-12-12 | U U-3226 | — | — | — | — | — | — |
| 9079912 | 2026-12-12 | U U-3227 | — | — | — | — | — | — |
| 9079912 | 2026-12-12 | U U-3228 | — | — | — | — | — | — |
| 9079912 | 2026-12-12 | U U-3230 | — | — | — | — | — | — |
| 9814722 | 2026-12-12 | U U-3226 | — | — | — | — | — | — |
| 9814722 | 2026-12-12 | U U-3230 | — | — | — | — | — | — |
| 9079912 | 2027-06-12 | — — | — | — | — | — | 2027-06-12 | — |
| 9079912 | 2027-06-12 | ORANGE_BOOK U-3226,U-3227,U-3228,U-3230 | N | Y | DS_EQUIVALENT Independent claims 1/3: ruxolitinib JAK1/JAK2 inhibition or signal blocking, without indication restriction. | — | 2027-06-12 | — |
| 9814722 | 2027-06-12 | — — | — | — | — | — | 2027-06-12 | — |
| 9814722 | 2027-06-12 | ORANGE_BOOK U-3226,U-3230 | N | N | U Process or use limited to a particular indication, combination, regimen, population or formulation; not whole-label anchor. | — | 2027-06-12 | — |
| 7598257 | 2027-12-24 | DS/DP/U U-3228 | — | — | — | — | — | — |
| 7598257 | 2027-12-24 | DS/DP/U U-3227 | — | — | — | — | — | — |
| 8415362 | 2027-12-24 | DS/DP — | — | — | — | — | — | — |
| 10016429 | 2028-06-12 | U U-3226 | — | — | — | — | — | — |
| 10016429 | 2028-06-12 | U U-3230 | — | — | — | — | — | — |
| 8722693 | 2028-06-12 | DS/DP — | — | — | — | — | — | — |
| 8822481 | 2028-06-12 | U U-3226 | — | — | — | — | — | — |
| 8822481 | 2028-06-12 | U U-3230 | — | — | — | — | — | — |
| 8822481 | 2028-06-12 | U U-1573 | — | — | — | — | — | — |
| 8822481 | 2028-06-12 | U U-3227 | — | — | — | — | — | — |
| 8822481 | 2028-06-12 | U U-3228 | — | — | — | — | — | — |
| 8829013 | 2028-06-12 | U U-1201 | — | — | — | — | — | — |
| 8829013 | 2028-06-12 | U U-3227 | — | — | — | — | — | — |
| 8829013 | 2028-06-12 | U U-3228 | — | — | — | — | — | — |
| 8829013 | 2028-06-12 | U U-1622 | — | — | — | — | — | — |
| 7598257 | 2028-06-24 | — — | — | — | — | — | 2028-06-24 | — |
| 7598257 | 2028-06-24 | ORANGE_BOOK U-3227,U-3228 | Y | N | TRUE_DS Independent chemical compound claim; no mandatory polymorph/formulation limitation. Matched to FDA exact-product estate. | — | 2028-06-24 | — |
| 8415362 | 2028-06-24 | — — | — | — | — | — | 2028-06-24 | — |
| 8415362 | 2028-06-24 | ORANGE_BOOK — | Y | N | TRUE_DS Independent chemical compound claim; no mandatory polymorph/formulation limitation. Matched to FDA exact-product estate. | — | 2028-06-24 | — |
| 10016429 | 2028-12-12 | — — | — | — | — | — | 2028-12-12 | — |
| 10016429 | 2028-12-12 | ORANGE_BOOK U-3226,U-3230 | N | N | U Process or use limited to a particular indication, combination, regimen, population or formulation; not whole-label anchor. | — | 2028-12-12 | — |
| 8722693 | 2028-12-12 | — — | — | — | — | — | 2028-12-12 | — |
| 8722693 | 2028-12-12 | ORANGE_BOOK — | N | N | DP Composition, salt, polymorph, dispersion or formulation claim; no automatic DS-equivalent promotion. | — | 2028-12-12 | — |
| 8822481 | 2028-12-12 | — — | — | — | — | — | 2028-12-12 | — |
| 8822481 | 2028-12-12 | ORANGE_BOOK U-1573,U-3226,U-3227,U-3228,U-3230 | N | Y | DS_EQUIVALENT Independent claims 1/8/15: ruxolitinib phosphate inhibition/modulation of JAK1/JAK2, no disease restriction; all approved JAKAFI and OPZELURA indications use this mechanism. | — | 2028-12-12 | — |
| 8829013 | 2028-12-12 | — — | — | — | — | — | 2028-12-12 | — |
| 8829013 | 2028-12-12 | ORANGE_BOOK U-1201,U-1622,U-3227,U-3228 | N | N | U Process or use limited to a particular indication, combination, regimen, population or formulation; not whole-label anchor. | — | 2028-12-12 | — |
Regulatory exclusivity
| Code | Start date | End date | Scope | Entire product | All indications | Full coverage date | Combination | Source |
|---|---|---|---|---|---|---|---|---|
| M-285 | — | 2025-12-19 | — | — | — | — | Source | |
| M-285 | — | 2025-12-19 | FDA posted date collected; scope not independently certified; preserved as context/tail. | — | — | — | — | Source |
| ODE-238 | — | 2026-05-24 | — | — | — | — | Source | |
| ODE-238 | — | 2026-05-24 | FDA posted date collected; scope not independently certified; preserved as context/tail. | — | — | — | — | Source |
| PED | — | 2026-06-19 | — | — | — | — | Source | |
| PED | — | 2026-06-19 | FDA posted date collected; scope not independently certified; preserved as context/tail. | — | — | — | — | Source |
| PED | — | 2026-11-24 | — | — | — | — | Source | |
| PED | — | 2026-11-24 | FDA posted date collected; scope not independently certified; preserved as context/tail. | — | — | — | — | Source |
| ODE-373 | — | 2028-09-22 | — | — | — | — | Source | |
| ODE-373 | — | 2028-09-22 | FDA posted date collected; scope not independently certified; preserved as context/tail. | — | — | — | — | Source |
| PED | — | 2029-03-22 | — | — | — | — | Source | |
| PED | — | 2029-03-22 | FDA posted date collected; scope not independently certified; preserved as context/tail. | — | — | — | — | Source |
2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE
Generic approval evidence
| Application / product | Event | Final date | Tentative date | Applicant | Authorized generic | Exact mapping | Source |
|---|---|---|---|---|---|---|---|
| No generic approval facts are linked to this product. | |||||||
Market Entry Information
API filings, authorized generics and linked regulatory milestones.
API Master Files & Certifications 0 records
Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.
| API | Holder / manufacturer | Holder country | Filing type | Number | Status | Filed date | Available for reference | Source | Last verified |
|---|---|---|---|---|---|---|---|---|---|
| No master-file or certification records are linked through public manufacturer portfolios. | |||||||||
Authorized Generics 0 records
Authorized generics are shown separately from independent ANDA approvals.
| Application / product | Applicant | Event / status | First marketed | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No authorized-generic records are linked to this product. | ||||||
Tentative ANDA Approvals 0 records
Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.
| Application / product | Applicant | Event / status | Tentative date | Follow-up final approval | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|---|
| No tentative-approval records are linked to this product. | |||||||
Paragraph IV Challenges 0 records
Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.
| Application / product | Applicant | Event / status | Certification event date | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No structured Paragraph IV certification events are linked in the available approval evidence. | ||||||
Final ANDA Approvals 0 records
Approval dates do not establish commercial launch. Product mapping is shown for each linked record.
| Application / product | Applicant | Event / status | Final approval date | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No final-approval records are linked to this product. | ||||||
Decision evidence (9)
| Type | Date | Role | Basis | Source |
|---|---|---|---|---|
| PATENT | 2027-06-12 | HISTORICAL_CONTEXT | Independent claims 1/3: ruxolitinib JAK1/JAK2 inhibition or signal blocking, without indication restriction. | Source |
| PATENT | 2027-06-12 | HISTORICAL_CONTEXT | Process or use limited to a particular indication, combination, regimen, population or formulation; not whole-label anchor. | Source |
| PATENT | 2028-06-24 | HISTORICAL_CONTEXT | Independent chemical compound claim; no mandatory polymorph/formulation limitation. Matched to FDA exact-product estate. | Source |
| PATENT | 2028-06-24 | HISTORICAL_CONTEXT | Independent chemical compound claim; no mandatory polymorph/formulation limitation. Matched to FDA exact-product estate. | Source |
| PATENT | 2028-12-12 | HISTORICAL_CONTEXT | Process or use limited to a particular indication, combination, regimen, population or formulation; not whole-label anchor. | Source |
| PATENT | 2028-12-12 | HISTORICAL_CONTEXT | Composition, salt, polymorph, dispersion or formulation claim; no automatic DS-equivalent promotion. | Source |
| PATENT | 2028-12-12 | CANONICAL_ANCHOR | Independent claims 1/8/15: ruxolitinib phosphate inhibition/modulation of JAK1/JAK2, no disease restriction; all approved JAKAFI and OPZELURA indications use this mechanism. | Source |
| PATENT | 2028-12-12 | HISTORICAL_CONTEXT | Process or use limited to a particular indication, combination, regimen, population or formulation; not whole-label anchor. | Source |
| REGULATORY_STATUS | 2028-12-12 | CANONICAL_DECISION | English description not available. | Source |
Independent legal-event information
Litigation & Settlement History
Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.
No litigation or settlement record currently linked to this product.